Insulet Corporation (PODD)
After hours:
| Previous close | 241.25 |
| Open | 237.88 |
| Bid | 233.27 x 800 |
| Ask | 242.17 x 900 |
| Day's range | 230.76 - 238.66 |
| 52-week range | 181.00 - 324.81 |
| Volume | |
| Avg. volume | 399,861 |
| Market cap | 16.254B |
| Beta (5Y monthly) | 0.72 |
| PE ratio (TTM) | 468.38 |
| EPS (TTM) | 0.50 |
| Earnings date | 03 Nov 2022 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 287.92 |
- Business Wire
Insulet to Announce Third Quarter 2022 Financial Results on November 3, 2022
ACTON, Mass., September 22, 2022--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced plans to release its financial results for the third quarter of 2022 on November 3, 2022 after the close of the financial markets. In connection with the release, management will host a conference call that day at 4:30 p.m. (Eastern Time).
- Business Wire
Insulet Announces CE Mark Approval for Omnipod® 5 Automated Insulin Delivery System
ACTON, Mass., September 20, 2022--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced it has received CE marking under the European Medical Device Regulation for its Omnipod 5 Automated Insulin Delivery System (Omnipod 5) for individuals aged two years and older with type 1 diabetes.
- Zacks
3 Reasons to Hold Insulet (PODD) Stock in Your Portfolio
Investors continue to be optimistic about Insulet (PODD) on Omnipod's continued market access expansion.
